Liver Cirrhosis, Biliary
FIBROSIS of the hepatic parenchyma due to obstruction of BILE flow (CHOLESTASIS) in the intrahepatic or extrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC; BILE DUCTS, EXTRAHEPATIC). Primary biliary cholangitis involves the destruction of small intra-hepatic bile ducts and decreased bile secretion. Secondary biliary cholangitis is produced by prolonged obstruction of large intrahepatic or extrahepatic bile ducts from a variety of causes.
Drugs by status
Approved for this indication (5)
Phase 4 trials (12)
Phase 3 trials (14)
Phase 2 trials (31)
- odevixibat
- apd-334
- bcd-085
- berberine
- e6011
- ffp104
- gkt137831
- sertraline
- tenofovir
- rosuvastatin
- baricitinib
- tropifexor
- moexipril
- nalmefene
- ni-0801
- Volixibat
- emtricitabine
- pentoxifylline
- ustekinumab
- umbilical cord mesenchymal stem cells
- autologous bone marrow derived mesenchymal cells
- edp-305
- rituximab
- raltegravir
- pemafibrate
- aldafermin
- cilofexor
- tqa3526
- maralixibat
- asc42
- +1 more
Phase 1 trials (9)
Other trials (3)
Organizations
Organization Involved with Phase 4 Indications (10)
Organization Involved with Phase 3 Indications (21)
- Axcan
- GlaxoSmithKline
- CymaBay Therapeutics, Inc.
- Genfit
- National Center for Research Resources (NCRR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Medical University of Graz
- Beijing Trendful Kangjian Medical Information Consulting Limited Company
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Tufts University
- University of Michigan
- University of Alberta
- University of Birmingham
- Mayo Clinic
- Capital Medical University
- St. Louis University
- Food and Drug Administration
- University of Montreal
- University of Paris
- People's Liberation Army of China
- The University of Texas, Dallas
Organization Involved with Phase 2 Indications (34)
- Shire
- Gilead Sciences
- Merck
- Eli Lilly
- Genentech
- Shionogi
- Albireo
- Novartis
- Arena Pharmaceuticals
- Biocad
- Fast Forward Pharmaceuticals
- Enanta Pharmaceuticals
- HighTide Biopharma Pty Ltd
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- NGM Biopharmaceuticals, Inc
- NovImmune SA
- Zydus Discovery DMCC
- EA Pharma Co., Ltd.
- Genkyotex Innovation SAS
- Ho Chi Minh City University of Medicine and Pharmacy
- Hoosier Cancer Research Network
- Newcastle University
- University of Florida
- University of Miami
- University of Rochester
- Vinmec International Hospital
- Moscow State University
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Gothenburg
- Department of Health, United Kingdom
- +4 more
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (6)